[HTML][HTML] Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled …
…, I Fuentes, A Ascaso, D Lora, N Imaz-Ayo… - The Lancet, 2021 - thelancet.com
Background To date, no immunological data on COVID-19 heterologous vaccination schedules
in humans have been reported. We assessed the immunogenicity and reactogenicity of …
in humans have been reported. We assessed the immunogenicity and reactogenicity of …
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded …
…, LIM Alcorta, MID Laviña, N Imaz-Ayo… - The Lancet Infectious …, 2022 - thelancet.com
Background Additional safe and efficacious vaccines are needed to control the COVID-19
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
[HTML][HTML] T cell activation, highly armed cytotoxic cells and a shift in monocytes CD300 receptors expression is characteristic of patients with severe COVID-19
…, I Seijas-Betolaza, J Nieto-Arana, N Imaz-Ayo… - Frontiers in …, 2021 - frontiersin.org
COVID-19 manifests with a wide diversity of clinical phenotypes characterized by dysfunctional
and exaggerated host immune responses. Many results have been described on the …
and exaggerated host immune responses. Many results have been described on the …
[HTML][HTML] Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated …
…, E Arana-Arri, S Meijide, N Imaz-Ayo… - The Lancet Regional …, 2023 - thelancet.com
Background A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown
to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study …
to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study …
[HTML][HTML] Reactogenicity and immunogenicity of BNT162b2 in subjects having received a first dose of ChAdOx1s: initial results of a randomised, adaptive, phase 2 trial …
…, I Fuentes-Camps, A Ascaso, D Lora, N Imaz-Ayo… - 2021 - papers.ssrn.com
Background: There are no immunological data on SARS-CoV-2 heterologous vaccinations
schedules in humans. We assessed the immunogenicity and reactogenicity of BNT162b2 (…
schedules in humans. We assessed the immunogenicity and reactogenicity of BNT162b2 (…
[HTML][HTML] Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a …
…, M Bermejo, MC de la Osa, N Imaz-Ayo… - …, 2022 - thelancet.com
Background There is no evidence to date on immunogenic response among individuals
who participated in clinical trials of COVID-19 experimental vaccines redirected to standard …
who participated in clinical trials of COVID-19 experimental vaccines redirected to standard …
Screening colonoscopy and risk of adverse events among individuals undergoing fecal immunochemical testing in a population-based program: A nested case …
E Arana-Arri, N Imaz-Ayo… - United European …, 2018 - journals.sagepub.com
Background Screening by means of biennial fecal occult blood test has provided a reduction
in overall colorectal cancer mortality. Notwithstanding, we should not underestimate the …
in overall colorectal cancer mortality. Notwithstanding, we should not underestimate the …
Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years
…, L Martínez-Indart, N Imaz-Ayo… - European journal of …, 2019 - journals.lww.com
Background The steady increase in colorectal cancer (CRC) could be reversed through
timely secondary prevention (screening) as a main strategy. The aims of this study were to …
timely secondary prevention (screening) as a main strategy. The aims of this study were to …
[HTML][HTML] Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the …
…, JR Arribas, N Imaz-Ayo… - …, 2022 - thelancet.com
Background The CombiVacS study was designed to assess immunogenicity and reactogenicity
of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a …
of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a …
[HTML][HTML] Efficacy and usability of eHealth Technologies in stroke survivors for prevention of a new stroke and improvement of self-management: phase III randomized …
…, A Gutiérrez-Ruiz, N Imaz-Ayo… - Methods and …, 2019 - mdpi.com
Background: Stroke is a leading cause of severe and long-term disability in developed countries.
Around 15 million people suffer a stroke each year, being most of them ischemic due to …
Around 15 million people suffer a stroke each year, being most of them ischemic due to …